Flagstar Bank NA vs Cassava Sciences Inc — how do they compare? Flagstar Bank NA trades at $14.32 (market cap $5.89B), while Cassava Sciences Inc trades at $0.94 (market cap $47.75M). The key difference: Flagstar Bank NA is far larger — about 123.4× Cassava Sciences Inc's market cap, and Flagstar Bank NA pays a 0.28% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLG | FLNA | |
|---|---|---|
Market Cap | $5.89B | $47.75M |
Sector | Financials | Health |
52-Week High | $15.36 | $4.64 |
52-Week Low | $10.72 | $0.87 |
Dividend Yield | 0.28% | — |
Enterprise Value | — | -$34.93M |
Signals from Pluang's Aura AI — not financial advice
Flagstar Bank (FLG) trades at $14.285, up 1.96% today, with a bullish technical signal from moving averages and a consensus analyst price target of $16.85. Recent Q2 2026 earnings missed estimates, but the bank reported its third consecutive profitable quarter, supported by loan growth and cost controls. A $250 million share repurchase program and dividend payments reflect strong capital management, while proprietary technology initiatives aim to bolster long-term growth.
The outlook is cautiously optimistic, with potential upside from execution on strategic initiatives and valuation support from a low P/B ratio of 0.77. Risks include earnings volatility, competitive pressures in regional banking, and sensitivity to interest rate changes. Analyst sentiment is positive with no sell ratings, but investors should monitor fee income trends and credit quality.
FLNA trades at $0.9973, up 0.23% with a bearish technical signal despite recent earnings beats. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though cash burn improved from -$33M to -$30M projected for 2026. Analyst consensus is strongly bullish with 8 buy ratings versus 4 hold ratings.
The outlook remains challenging due to persistent losses and negative cash flow, but analyst optimism and continued progress in TSC-related epilepsy therapies provide potential catalysts. Key risks include execution challenges in clinical development and the company's ability to secure additional funding.
Trailing returns across standard periods
Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.
Read more on FLG →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →